Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuronal synaptic transmission is the fundamental physiological process by which neurons communicate with each other and with effector cells at specialized junctions called synapses (StatPearls, 2023). This process typically involves the conversion of an electrical action potential in the presynaptic neuron into a chemical signal through the regulated release of neurotransmitters from synaptic vesicles into the synaptic cleft (Molecular Biology of the Cell, 2002). These neurotransmitters then diffuse across the cleft and bind to specific ionotropic or metabotropic receptors on the postsynaptic membrane, eliciting a biological response such as an excitatory or inhibitory postsynaptic potential (NIH, 2022). Because it encompasses a vast array of molecular components—including receptors, transporters, and enzymes—neuronal synaptic transmission is considered a biological pathway rather than a single therapeutic target. Dysfunction in various stages of this transmission is central to the pathogenesis of numerous conditions, including epilepsy, schizophrenia, and neurodegenerative diseases like Alzheimer's (Nature Reviews Neuroscience, 2014). Pharmacological agents frequently target specific elements of this process, such as reuptake transporters or receptor subunits, to modulate signal intensity and duration (PubChem, 2024). For example, selective serotonin reuptake inhibitors (SSRIs) increase the availability of serotonin in the synapse, while NMDA receptor antagonists modulate glutamatergic signaling (PubMed, 2021). Therapeutic challenges include achieving specificity for particular brain regions and avoiding systemic side effects or compensatory mechanisms like receptor downregulation.
Drugs modulate neuronal synaptic transmission by acting as agonists or antagonists at neurotransmitter receptors, inhibiting neurotransmitter reuptake, or altering neurotransmitter synthesis and degradation (StatPearls, 2023).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuronal synaptic transmission.